Showing 1240 – 1250 of 1304 results
-
MDxHealth SA Initiation
William Blair initiated research coverage of MDxHealth SA (MDXH $2.86), a commercial-stage diagnostics company providing actionable molecular diagnostic information to personalize diagnosis and treatment of prostrate cancer and other urologic diseases.
-
NAPCO Security Technologies Inc Initiation
William Blair initiated research coverage of NAPCO Security Technologies, Inc. (NSSC $32.46), a provider of commercial and residential intrusion, fire, access control, and door locking hardware and services.
-
Mesoblast Limited Initiation
William Blair initiated research coverage of Mesoblast Limited (MESO $3.03). Mesoblast is an Australia-based biotechnology company focused on the development of allogeneic mesenchymal lineage cells for the treatment of severe and life-threatening inflammatory diseases.
-
ARS Pharmaceuticals Inc Initiation
William Blair initiated research coverage of ARS Pharmaceuticals, Inc. (SPRY $8.50), a clinical-stage biopharmaceutical company focused on developing treatments that are safe, effective, needle-free, easy to carry, and simple to administer for people affected by severe allergic reactions.
-
Affirm Holdings Inc and SoFi Technologies Inc Initations
William Blair initiated research coverage of Affirm Holdings, Inc. (AFRM $54.69) and SoFi Technologies, Inc. (SOFI $14.07), two leaders in digital finance.
-
Straumann Holding AG Initiation
William Blair initiated research coverage of Straumann Holding AG (STMN-SWX CHF 129.45), a global leader in dentistry with a portfolio of tooth replacement and orthodontic solutions.
-
Cboe Global Markets Inc Initiation
William Blair initiated research coverage of Cboe Global Markets, Inc. (CBOE $190.84), a leading derivatives and securities exchange network that provides trading, clearing, data, and technology solutions to a broad range of market participants globally.
-
Elevation Oncology Inc Initiation
William Blair initiated research coverage of Elevation Oncology, Inc. (ELEV $0.56), a clinical-stage biotechnology company advancing a Phase I antibody-drug conjugate (ADC) against claudin 18.2, initially targeting gastric cancer/gastroesophageal junction (GEJ) adenocarcinoma with pancreatic cancer as an expansion opportunity.
-
Denali Therapeutics Inc Initiation
William Blair initiated research coverage of Denali Therapeutics Inc. (DNLI $20.38), a clinical-stage biotechnology company developing treatments for CNS and other indications by leveraging its unique blood–brain barrier penetrating technology platform.
-
Waste Connections Inc Initiation
William Blair initiated research coverage of Waste Connections, Inc. (WCN $196.51), a vertically integrated solid waste, recycling, and E&P waste provider.